These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
589 related articles for article (PubMed ID: 33391463)
41. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500 [TBL] [Abstract][Full Text] [Related]
42. Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells. Hieber C; Mustafa AM; Neuroth S; Henninger S; Wollscheid HP; Zabkiewicz J; Lazenby M; Alvares C; Mahboobi S; Butter F; Brenner W; Bros M; Krämer OH Biomed Pharmacother; 2024 Aug; 177():117076. PubMed ID: 38971011 [TBL] [Abstract][Full Text] [Related]
43. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805 [TBL] [Abstract][Full Text] [Related]
44. Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti-Acute Myeloid Leukemia Efficacy In Vitro and In Vivo. Cao ZX; Wen Y; He JL; Huang SZ; Gao F; Guo CJ; Liu QQ; Zheng SW; Gong DY; Li YZ; Zhang RQ; Chen JP; Peng C Mol Pharmacol; 2019 Nov; 96(5):589-599. PubMed ID: 31462456 [TBL] [Abstract][Full Text] [Related]
45. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014 [TBL] [Abstract][Full Text] [Related]
46. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207 [TBL] [Abstract][Full Text] [Related]
47. N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants. Wang X; DeFilippis RA; Leung YK; Shah NP; Li HY Bioorg Chem; 2024 Feb; 143():106966. PubMed ID: 37995643 [TBL] [Abstract][Full Text] [Related]
48. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594 [TBL] [Abstract][Full Text] [Related]
52. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254 [TBL] [Abstract][Full Text] [Related]
53. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850 [TBL] [Abstract][Full Text] [Related]
55. Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML. Wang A; Li X; Chen C; Wu H; Qi Z; Hu C; Yu K; Wu J; Liu J; Liu X; Hu Z; Wang W; Wang W; Wang W; Wang L; Wang B; Liu Q; Li L; Ge J; Ren T; Zhang S; Xia R; Liu J; Liu Q J Med Chem; 2017 Oct; 60(20):8407-8424. PubMed ID: 28956923 [TBL] [Abstract][Full Text] [Related]
57. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. Nguyen B; Williams AB; Young DJ; Ma H; Li L; Levis M; Brown P; Small D Oncotarget; 2017 Feb; 8(7):10931-10944. PubMed ID: 28077790 [TBL] [Abstract][Full Text] [Related]
58. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638 [TBL] [Abstract][Full Text] [Related]
59. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling. Xu Y; Wang P; Li M; Wu Z; Li X; Shen J; Xu R Biomed Pharmacother; 2021 Jan; 133():111054. PubMed ID: 33254022 [TBL] [Abstract][Full Text] [Related]
60. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]